Fingolimod effects on left ventricular function in multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 2, 2016, Pages 201-211

  Racca, Vittorio ^a   Di Rienzo, Marco ^a   Cavarretta, Rosella ^a   Toccafondi, Anastasia ^a   Vaini, Emanuele ^a   Ferratini, Maurizio ^a   Rovaris, Marco ^a  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

cardiotoxicity; drug safety; drug side effects; Fingolimod; left ventricular systolic function; multiple sclerosis; ventricular ejection fraction

Indexed keywords

FINGOLIMOD; NATALIZUMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; BODY MASS; CORRELATIONAL STUDY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; EXPANDED DISABILITY STATUS SCALE; HEART CONDUCTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HERPES ZOSTER; LIVER NECROSIS; MIDDLE AGED; QT PROLONGATION; SINGLE DRUG DOSE; TRICUSPID VALVE REGURGITATION; YOUNG ADULT; CASE CONTROL STUDY; DRUG EFFECTS; HEART STROKE VOLUME; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHYSIOLOGY; PROSPECTIVE STUDY; SYSTOLE;

ADULT; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; PROSPECTIVE STUDIES; STROKE VOLUME; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 84957094397     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515587753     Document Type: Article

References (25)

1. Koch-Henriksen N, Sorensen PS,. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532.
2. Chun J, Brinkmann V,. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 2011; 12: 213-228.
3. Kappos L, Radue EW, O'Connor P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
4. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-56; Erratum: Lancet Neurol 2013; 13: 536.
5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
6. Chun J, Hartung HP,. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
7. Brinkmann V,. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173-1182.
8. Brinkmann V, Baumruker T,. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006; 6: 244-250.
9. Mazurais D, Roberts P, Gout B, et al. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002; 50: 661-669.
10. Liliom K, Sun G, Bunemann M, et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 2001; 355: 189-197.
11. Koyrakh L, Roman MI, Brinkmann V, et al. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5: 529-536.
12. Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006; 46: 895-904.
13. Collins W, Cohen J, O'Connor P, et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 1 and 3 studies (P843). Mult Scler 2010; 16: S295.
14. Gialafos E, Gerakoulis S, Grigoriou A, et al. Intermittent atrioventricular block following fingolimod initiation. Case Rep Neurol Med 2014: 1-4. DOI: 10.1155/2014/191305.
15. Pelletier D, Hafler DA,. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366: 339-347.
16. Espinosa PS, Berger JR,. Delayed fingolimod-associated asystole. Mult Scler 2011; 17: 1387-1389.
17. Food and Drug Administration. FDA drug safety communication: safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod). http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm (. accessed 20 December 2011).
18. European Medicines Agency. European Medicines Agency starts review of Gilenya (fingolimod). 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public-health-alerts/2012/01/human-pha-detail-000050.jsp&mid=WC0b01ac058001d126 (. accessed 25 October 2012).
19. Laroni A, Brogi D, Morra VB, et al. EAP Investigators. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol 2014; 14: 65.
20. Ward MD, Jones DE, Goldman MD,. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf 2014; 13: 989-98.
21. Rossi S, Rocchi C, Studer V, et al. The autonomic balance predicts cardiac responses after the first dose of fingolimod. Mult Scler 2015; 21: 206-216.
22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
23. Quiñones MA, Otto CM, Stoddard M, et al. Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167-184.
24. Oh J, O'Connor PW,. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2013; 27: 591-609.
25. Schmouder R, Hariry S, David OJ,. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol 2012; 68: 355-362.